8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Mar 24, 2026·SEC
MaxCyte, Inc.(MXCT)Earnings, Financials & Key Ratios
MXCT•NASDAQ
Price updated Jun 19, 2026
AboutMaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.Show more
- Revenue$33M-14.5%
- EBITDA-$40M+13.5%
- Net Income-$45M-8.7%
- EPS (Diluted)-0.42-7.7%
- Gross Margin81.16%-0.6%
- EBITDA Margin-121.55%-1.2%
- Operating Margin-137.12%-3.5%
- Net Margin-135.14%-27.1%
- ROE-23.63%-26.2%
MXCT Key Insights
MaxCyte, Inc. (MXCT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Profits declining 30.4% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MXCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MXCT Price & Volume
MaxCyte, Inc. (MXCT) stock price & volume — 10-year historical chart
Loading chart...
MXCT Growth Metrics
MaxCyte, Inc. (MXCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years13.52%
5 Years4.76%
3 Years-9.3%
TTM-14.3%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM6.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.33%
Return on Capital
10 Years-32.56%
5 Years-16.81%
3 Years-20.7%
Last Year-21.99%
MXCT Recent Earnings
MaxCyte, Inc. (MXCT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.04+60.0%
$0.10
Rev
$10M+32.5%
$7M
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$0.06+25.0%
$0.08
Rev
$7M-19.6%
$9M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.12-9.1%
$0.11
Rev
$7M-27.4%
$9M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.12-20.0%
$0.10
Rev
$9M-17.9%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.04vs $0.10+60.0% | $10Mvs $7M+32.5% |
| Q2 2026 | Mar 24, 2026 | $0.06vs $0.08+25.0% | $7Mvs $9M-19.6% |
| Q4 2025 | Nov 12, 2025 | $0.12vs $0.11-9.1% | $7Mvs $9M-27.4% |
| Q3 2025 | Aug 6, 2025 | $0.12vs $0.10-20.0% | $9Mvs $10M-17.9% |
Based on last 12 quarters of dataView full earnings history →
MXCT Peer Comparison
MaxCyte, Inc. (MXCT) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BTBT | 706.64M | 2.17 | -7 | -30.65% | -146.01% | -0.11% | 0.16 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 PSNL | 936M | 10.54 | -11.58 | -100% | -148.11% | -43.52% | 0.12 | |
 BCYC | 277.05M | 4.00 | -1.27 | 105.77% | -344.95% | -35.74% | 0.03 | |
 XNCR | 927M | 12.64 | -10.19 | 13.65% | -185.71% | -28.77% | 0.30 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare MXCT vs Peers
MaxCyte, Inc. (MXCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MXCT Income Statement
MaxCyte, Inc. (MXCT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 13.98M | 16.67M | 21.62M | 26.17M | 33.89M | 44.26M | 41.29M | 38.63M | 33.03M | 32.29M |
Revenue Growth % | 13.98% | 19.18% | 29.72% | 21.04% | 29.52% | 30.59% | -6.72% | -6.44% | -14.5% | -14.3% |
Cost of Goods Sold | 1.45M | 1.84M | 2.5M | 2.77M | 3.65M | 5.1M | 4.74M | 7.1M | 6.22M | 6.23M |
COGS % of Revenue | 10.39% | 11.04% | 11.56% | 10.57% | 10.76% | 11.52% | 11.49% | 18.38% | 18.84% | - |
Gross Profit | 12.53M▲ 0% | 14.83M▲ 18.3% | 19.12M▲ 29.0% | 23.4M▲ 22.4% | 30.25M▲ 29.2% | 39.16M▲ 29.5% | 36.55M▼ 6.7% | 31.53M▼ 13.7% | 26.8M▼ 15.0% | 26.06M▲ 0% |
Gross Margin % | 89.61% | 88.96% | 88.44% | 89.43% | 89.24% | 88.48% | 88.51% | 81.62% | 81.16% | 80.7% |
Gross Profit Growth % | 14.32% | 18.31% | 28.96% | 22.39% | 29.25% | 29.48% | -6.68% | -13.73% | -14.98% | - |
Operating Expenses | 21.82M | 23.25M | 31.54M | 34.46M | 48.44M | 66.52M | 84.84M | 82.72M | 72.09M | 64.71M |
OpEx % of Revenue | 156.05% | 139.51% | 145.89% | 131.68% | 142.9% | 150.3% | 205.5% | 214.16% | 218.28% | - |
Selling, General & Admin | 10.54M | 12.01M | 13.41M | 15.7M | 31.68M | 44.48M | 57.04M | 56.35M | 47.04M | 42.18M |
SG&A % of Revenue | 75.36% | 72.05% | 62.01% | 59.99% | 93.46% | 100.5% | 138.16% | 145.89% | 142.43% | - |
Research & Development | 11.28M | 11.24M | 17.59M | 17.73M | 15.41M | 19.51M | 23.82M | 22.23M | 20.82M | 18.78M |
R&D % of Revenue | 80.69% | 67.46% | 81.37% | 67.77% | 45.46% | 44.09% | 57.68% | 57.54% | 63.05% | - |
Other Operating Expenses | 0 | 0 | 541.3K | 1.03M | 1.35M | 2.53M | 3.98M | 4.14M | 4.23M | 3M |
Operating Income | -9.29M▲ 0% | -8.42M▲ 9.3% | -12.42M▼ 47.4% | -11.06M▲ 11.0% | -18.19M▼ 64.5% | -27.36M▼ 50.4% | -48.3M▼ 76.5% | -51.2M▼ 6.0% | -45.28M▲ 11.5% | -38.66M▲ 0% |
Operating Margin % | -66.44% | -50.55% | -57.44% | -42.25% | -53.66% | -61.82% | -116.98% | -132.54% | -137.12% | -119.73% |
Operating Income Growth % | -241.18% | 9.33% | -47.42% | 10.98% | -64.5% | -50.43% | -76.53% | -6% | 11.55% | - |
EBITDA | -9.15M | -8.08M | -11.81M | -10.01M | -16.76M | -24.66M | -44.13M | -46.41M | -40.14M | -34.18M |
EBITDA Margin % | -65.42% | -48.48% | -54.61% | -38.25% | -49.46% | -55.72% | -106.88% | -120.14% | -121.55% | -105.85% |
EBITDA Growth % | -249.5% | 11.67% | -46.1% | 15.22% | -67.5% | -47.11% | -78.92% | -5.16% | 13.5% | 25.93% |
D&A (Non-Cash Add-back) | 142.9K | 344K | 613.5K | 1.05M | 1.42M | 2.7M | 4.17M | 4.79M | 5.14M | 4.48M |
EBIT | -9.29M | -8.25M | -12.21M | -10.99M | -18.04M | -27.36M | -48.3M | -51.2M | -45.28M | -40.5M |
Net Interest Income | -625.3K | -444.3K | -475K | -759.7K | -893.6K | 3.79M | 10.38M | 10.14M | 7.27M | 6.67M |
Interest Income | 0 | 170.3K | 206.1K | 65.9K | 150.8K | 3.92M | 10.38M | 10.14M | 7.27M | 6.67M |
Interest Expense | 625.3K | 614.6K | 681.1K | 825.6K | 1.04M | 126.9K | 0 | 0 | 0 | 0 |
Other Income/Expense | -625.3K | -444.3K | -475K | -759.7K | -893.6K | 3.79M | 10.38M | 10.14M | 655K | -463K |
Pretax Income | -9.92M▲ 0% | -8.87M▲ 10.6% | -12.89M▼ 45.4% | -11.82M▲ 8.4% | -19.08M▼ 61.5% | -23.57M▼ 23.5% | -37.92M▼ 60.9% | -41.05M▼ 8.3% | -44.63M▼ 8.7% | -39.12M▲ 0% |
Pretax Margin % | -70.91% | -53.21% | -59.64% | -45.15% | -56.3% | -53.25% | -91.85% | -106.29% | -135.14% | -121.16% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -9.92M▲ 0% | -8.87M▲ 10.6% | -12.89M▼ 45.4% | -11.82M▲ 8.4% | -19.08M▼ 61.5% | -23.57M▼ 23.5% | -37.92M▼ 60.9% | -41.05M▼ 8.3% | -44.63M▼ 8.7% | -39.12M▲ 0% |
Net Margin % | -70.91% | -53.21% | -59.64% | -45.15% | -56.3% | -53.25% | -91.85% | -106.29% | -135.14% | -121.16% |
Net Income Growth % | -196.43% | 10.57% | -45.39% | 8.36% | -61.49% | -23.52% | -60.89% | -8.26% | -8.71% | 6.39% |
Net Income (Continuing) | -9.92M | -8.87M | -12.89M | -11.82M | -19.08M | -23.57M | -37.92M | -41.05M | -44.63M | -39.12M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.20▲ 0% | -0.17▲ 15.0% | -0.24▼ 41.2% | -0.18▲ 25.0% | -0.22▼ 22.2% | -0.19▲ 13.6% | -0.37▼ 94.7% | -0.39▼ 5.4% | -0.42▼ 7.7% | -0.37▲ 0% |
EPS Growth % | -100.4% | 15% | -41.18% | 25% | -22.22% | 13.64% | -94.74% | -5.41% | -7.69% | 6.33% |
EPS (Basic) | -0.20 | -0.17 | -0.24 | -0.18 | -0.22 | -0.19 | -0.37 | -0.39 | -0.42 | - |
Diluted Shares Outstanding | 48.64M | 51.18M | 56.4M | 69.46M | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M | 106.88M |
Basic Shares Outstanding | 48.64M | 51.18M | 56.4M | 69.46M | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M | 106.88M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MXCT Balance Sheet
MaxCyte, Inc. (MXCT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 30.55M | 22.45M | 24.45M | 45.25M | 270.43M | 252.27M | 190.19M | 171.68M | 118.37M | 122.94M |
Cash & Short-Term Investments | 25.34M | 14.44M | 16.71M | 34.76M | 255.04M | 227.34M | 168.29M | 154.48M | 103.04M | 14.56M |
Cash Only | 25.34M | 11.25M | 15.21M | 18.76M | 47.78M | 11.06M | 46.51M | 27.88M | 20.07M | 14.56M |
Short-Term Investments | 0 | 3.19M | 1.5M | 16.01M | 207.26M | 216.28M | 121.78M | 126.6M | 82.98M | 0 |
Accounts Receivable | 3.2M | 4.9M | 3.24M | 5.17M | 6.88M | 11.18M | 5.78M | 4.68M | 3.5M | 4.25M |
Days Sales Outstanding | 83.4 | 107.41 | 54.77 | 72.14 | 74.06 | 92.16 | 51.08 | 44.24 | 38.71 | 61.63 |
Inventory | 1.35M | 2.24M | 3.7M | 4.32M | 5.2M | 8.58M | 12.23M | 8.91M | 7.55M | 7.63M |
Days Inventory Outstanding | 338.35 | 444.9 | 540.64 | 569.3 | 520.83 | 614.37 | 941.29 | 458.25 | 442.73 | 449.98 |
Other Current Assets | 665.8K | 863.7K | 797.1K | 0 | 0 | 1.91M | 3.9M | 3.61M | 4.28M | 96.5M |
Total Non-Current Assets | 847.6K | 1.82M | 5.53M | 6.53M | 13.69M | 34.39M | 78.08M | 67.79M | 84.14M | 71.54M |
Property, Plant & Equipment | 847.6K | 1.82M | 5.53M | 6.49M | 13.37M | 33.58M | 34.75M | 30.47M | 28.45M | 27.34M |
Fixed Asset Turnover | 16.50x | 9.17x | 3.91x | 4.03x | 2.53x | 1.32x | 1.19x | 1.27x | 1.16x | 1.11x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 650K | 783K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 42.94M | 35.78M | 52.57M | 184.25M |
Other Non-Current Assets | 0 | 0 | 0 | 33.9K | 316.7K | 809K | 388K | 1.53M | 2.47M | 2.61M |
Total Assets | 31.4M▲ 0% | 24.27M▼ 22.7% | 29.99M▲ 23.6% | 51.78M▲ 72.7% | 284.12M▲ 448.7% | 286.65M▲ 0.9% | 268.27M▼ 6.4% | 239.47M▼ 10.7% | 202.51M▼ 15.4% | 194.47M▲ 0% |
Asset Turnover | 0.45x | 0.69x | 0.72x | 0.51x | 0.12x | 0.15x | 0.15x | 0.16x | 0.16x | 0.16x |
Asset Growth % | 95.35% | -22.71% | 23.56% | 72.68% | 448.7% | 0.89% | -6.41% | -10.74% | -15.44% | -57.62% |
Total Current Liabilities | 7.24M | 6.57M | 9.34M | 11.61M | 15.62M | 15.43M | 17.86M | 15.78M | 14.27M | 10.21M |
Accounts Payable | 4.33M | 1.03M | 2.09M | 890.2K | 1.82M | 292K | 743K | 1.36M | 1.4M | 1.2M |
Days Payables Outstanding | 1.09K | 204.74 | 305.15 | 117.43 | 182.16 | 20.91 | 57.19 | 69.81 | 82.19 | 74.6 |
Short-Term Debt | 850.9K | 0 | 0 | 0 | 0 | 0 | 0 | 864K | 1.46M | 1.37M |
Deferred Revenue (Current) | 2.06M | 2.45M | 3.19M | 4.84M | 6.75M | 0 | 5.07M | 5.25M | 3.6M | 14.71M |
Other Current Liabilities | -850.9K | 0 | 0 | 0 | 0 | 6.71M | 0 | 8.3M | 7.81M | 4.37M |
Current Ratio | 4.22x | 3.42x | 2.62x | 3.90x | 17.32x | 16.35x | 10.65x | 10.88x | 8.30x | 12.04x |
Quick Ratio | 4.03x | 3.07x | 2.22x | 3.52x | 16.98x | 15.80x | 9.97x | 10.32x | 7.77x | 11.29x |
Cash Conversion Cycle | -666.14 | 347.57 | 290.26 | 524.01 | 412.73 | 685.62 | 935.18 | 432.68 | 399.26 | 437.02 |
Total Non-Current Liabilities | 4.56M | 5.41M | 7.04M | 6.94M | 5.61M | 17.26M | 18.25M | 17.44M | 16.75M | 16.38M |
Long-Term Debt | 4.18M | 5.06M | 4.9M | 4.92M | 0 | 0 | 0 | 0 | 0 | 16.11M |
Capital Lease Obligations | 0 | 0 | 1.81M | 1.38M | 5.15M | 15.94M | 17.97M | 17.17M | 16.49M | 50.53M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 384.5K | 357.3K | 338.1K | 646.6K | 450.2K | 1.32M | 283K | 274K | 263K | 262K |
Total Liabilities | 11.8M | 11.99M | 16.38M | 18.55M | 21.22M | 32.69M | 36.11M | 33.22M | 31.02M | 26.59M |
Total Debt | 5.03M | 5.06M | 7.21M | 6.97M | 5.68M | 16.09M | 18.74M | 18.03M | 17.94M | 17.49M |
Net Debt | -20.31M | -6.19M | -8M | -11.79M | -42.1M | 5.03M | -27.76M | -9.85M | -2.12M | 2.93M |
Debt / Equity | 0.26x | 0.41x | 0.53x | 0.21x | 0.02x | 0.06x | 0.08x | 0.09x | 0.10x | 0.10x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.51x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.09x |
Interest Coverage | -14.86x | -13.43x | -17.93x | -13.31x | -17.27x | -215.61x | - | - | - | - |
Total Equity | 19.6M▲ 0% | 12.28M▼ 37.3% | 13.6M▲ 10.7% | 33.23M▲ 144.3% | 262.9M▲ 691.3% | 253.97M▼ 3.4% | 232.17M▼ 8.6% | 206.25M▼ 11.2% | 171.49M▼ 16.9% | 167.89M▲ 0% |
Equity Growth % | 285.5% | -37.33% | 10.75% | 144.27% | 691.25% | -3.4% | -8.58% | -11.16% | -16.85% | -61.95% |
Book Value per Share | 0.40 | 0.24 | 0.24 | 0.48 | 2.90 | 2.50 | 2.25 | 1.97 | 1.61 | 1.57 |
Total Shareholders' Equity | 19.6M | 12.28M | 13.6M | 33.23M | 262.9M | 253.97M | 232.17M | 206.25M | 171.49M | 167.89M |
Common Stock | 509K | 513.3K | 574K | 773.8K | 1.01M | 1.02M | 1.04M | 1.06M | 1.07M | 1.07M |
Retained Earnings | -61.64M | -70.51M | -83.41M | -95.22M | -114.3M | -137.88M | -175.8M | -216.85M | -261.48M | -266.23M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MXCT Cash Flow Statement
MaxCyte, Inc. (MXCT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.68M | -10.49M | -8.8M | -8.78M | -10.68M | -14.78M | -21.69M | -27.61M | -34.41M | -28.17M |
Operating CF Margin % | -69.2% | -62.92% | -40.71% | -33.56% | -31.51% | -33.4% | -52.52% | -71.48% | -104.19% | - |
Operating CF Growth % | -314.44% | -8.37% | 16.07% | 0.23% | -21.61% | -38.42% | -46.7% | -27.32% | -24.63% | -64.72% |
Net Income | -9.92M | -8.87M | -12.89M | -11.82M | -19.08M | -23.57M | -37.92M | -41.05M | -44.63M | -39.12M |
Depreciation & Amortization | 142.9K | 344K | 613.5K | 1.05M | 1.42M | 2.7M | 4.57M | 4.32M | 5.14M | 4.68M |
Stock-Based Compensation | 514.5K | 1.32M | 1.75M | 2.47M | 7.96M | 0 | 13.98M | 0 | 9.21M | 706K |
Deferred Taxes | 0 | 96.4K | 37.3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 101.3K | 74.7K | 76.9K | 373K | 664.6K | 9.3M | -6.13M | 9.88M | 1.99M | 9.6M |
Working Capital Changes | -518.8K | -3.46M | 1.61M | -858.2K | -1.64M | -3.21M | 3.82M | -751K | -6.12M | -4.03M |
Change in Receivables | -784.9K | -1.95M | 1.59M | -1.81M | -1.71M | -6.69M | 7.14M | 1.23M | 1.15M | 1.24M |
Change in Inventory | -174.9K | -1.29M | -1.89M | -890.6K | -1.41M | -3.49M | -4.53M | 1.36M | 575K | -336K |
Change in Payables | 849K | -689.1K | 1.05M | 391K | 2.09M | -149.7K | 3.25M | -1.88M | -3.72M | -1.77M |
Cash from Investing | -609.7K | -3.83M | 454.5K | -16.58M | -195.01M | -24.82M | 54.98M | 6.93M | 25.93M | 19.06M |
Capital Expenditures | -609.7K | -709.7K | -1.27M | -2.07M | -3.83M | -18.48M | -3.7M | -1.65M | -1.77M | -1.34M |
CapEx % of Revenue | 4.36% | 4.26% | 5.88% | 7.92% | 11.31% | 41.75% | 8.96% | 4.27% | 5.35% | 4.14% |
Acquisitions | 0 | 0 | -1.73M | 0 | 0 | 0 | 0 | 0 | -1.77M | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -3.12M | 1.73M | 0 | 4.6K | 0 | 9K | 0 | 0 | 0 |
Cash from Financing | 23.9M | 226.8K | 12.31M | 28.9M | 234.72M | 2.89M | 2.14M | 2.06M | 656K | 278K |
Debt Issued (Net) | -14.3K | -3.2K | -152.2K | -63.7K | -4.99M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 23.9M | 0 | 12.33M | 28.57M | 236.08M | 2.89M | 269K | 2.06M | 656K | 278K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 16.2K | 230K | 132.7K | 401K | 3.63M | 0 | 1.87M | 0 | 0 | 0 |
Net Change in Cash | 13.61M▲ 0% | -14.09M▼ 203.5% | 3.96M▲ 128.1% | 3.54M▼ 10.6% | 29.03M▲ 719.0% | -36.72M▼ 226.5% | 35.44M▲ 196.5% | -18.62M▼ 152.5% | -7.82M▲ 58.0% | -8.83M▲ 0% |
Free Cash Flow | -10.29M▲ 0% | -11.2M▼ 8.8% | -10.07M▲ 10.0% | -10.85M▼ 7.7% | -14.51M▼ 33.7% | -33.26M▼ 129.2% | -25.39M▲ 23.7% | -29.26M▼ 15.3% | -36.18M▼ 23.6% | -29.5M▲ 0% |
FCF Margin % | -73.56% | -67.18% | -46.59% | -41.48% | -42.82% | -75.15% | -61.49% | -75.75% | -109.54% | -91.38% |
FCF Growth % | -302.8% | -8.85% | 10.03% | -7.75% | -33.72% | -129.16% | 23.67% | -15.26% | -23.64% | 10.47% |
FCF per Share | -0.21 | -0.22 | -0.18 | -0.16 | -0.16 | -0.33 | -0.25 | -0.28 | -0.34 | -0.28 |
FCF Conversion (FCF/Net Income) | 0.98x | 1.18x | 0.68x | 0.74x | 0.56x | 0.63x | 0.57x | 0.67x | 0.77x | 0.75x |
Interest Paid | 0 | 0 | 0 | 421.4K | 420.9K | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MXCT Key Ratios
MaxCyte, Inc. (MXCT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -80.36% | -55.64% | -99.64% | -50.47% | -12.89% | -9.12% | -15.6% | -18.73% | -23.63% | -22.03% |
Return on Invested Capital (ROIC) | - | -235.1% | -159.34% | -61.34% | -11.26% | -8.55% | -15.63% | -19.16% | -18.57% | -16.11% |
Gross Margin | 89.61% | 88.96% | 88.44% | 89.43% | 89.24% | 88.48% | 88.51% | 81.62% | 81.16% | 80.7% |
Net Margin | -70.91% | -53.21% | -59.64% | -45.15% | -56.3% | -53.25% | -91.85% | -106.29% | -135.14% | -121.16% |
Debt / Equity | 0.26x | 0.41x | 0.53x | 0.21x | 0.02x | 0.06x | 0.08x | 0.09x | 0.10x | 0.10x |
Interest Coverage | -14.86x | -13.43x | -17.93x | -13.31x | -17.27x | -215.61x | - | - | - | - |
FCF Conversion | 0.98x | 1.18x | 0.68x | 0.74x | 0.56x | 0.63x | 0.57x | 0.67x | 0.77x | 0.75x |
Revenue Growth | 13.98% | 19.18% | 29.72% | 21.04% | 29.52% | 30.59% | -6.72% | -6.44% | -14.5% | -14.3% |
Related:MXCT Dividend History·MXCT Revenue History·MXCT Price History·MXCT P/E History·MXCT Financial Ratios·MXCT Institutional Holders
MXCT SEC Filings & Documents
MaxCyte, Inc. (MXCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
MXCT Frequently Asked Questions
MaxCyte, Inc. (MXCT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MaxCyte, Inc. (MXCT) reported $32.3M in revenue for fiscal year 2025. This represents a 538% increase from $5.1M in 2012.
MaxCyte, Inc. (MXCT) saw revenue decline by 14.5% over the past year.
MaxCyte, Inc. (MXCT) reported a net loss of $39.1M for fiscal year 2025.
Dividend & Returns
MaxCyte, Inc. (MXCT) has a return on equity (ROE) of -23.6%. Negative ROE indicates the company is unprofitable.
MaxCyte, Inc. (MXCT) had negative free cash flow of $29.5M in fiscal year 2025, likely due to heavy capital investments.